Impact Factor 2023: 1.5
Current issue – 12/2024
Contrast-enhanced ultrasound of the liver: Vascular pathologies and interventions
Ehsan Safai Zadeh, Helmut Prosch, Ahmed Ba-Ssalamah et al.
Over the past two decades, contrast-enhanced ultrasound (CEUS) has been established as a method complementary to B-mode ultrasound and color Doppler sonography for diagnosing vascular liver pathologies and interventions. Considering the limitations of ultrasound, CEUS presents a similar alternative to other imaging modalities, such as computed tomography and magnetic resonance imaging, for evaluating vascular pathologies, guiding interventions, identifying complications, and assessing outcomes post intervention. Due to its widespread availability and the absence of radiation exposure, CEUS should be employed as a primary modality. Zadeh et al. elucidate the application of CEUS in diagnosing vascular pathologies and interventional procedures.
2-Hydroxyglutarate as an MR spectroscopic predictor of an IDH mutation in gliomas
Jochen Bauer, Heiner N. Raum, Harald Kugel et al.
The mutated enzyme isocitrate dehydrogenase (IDH) 1 and 2 has been detected in various tumor entities such as gliomas and can convert α-ketoglutarate into the oncometabolite 2-hydroxyglutarate (2-HG). This neuro-oncologically significant metabolic product can be detected by MR spectroscopy and is therefore suitable for noninvasive glioma classification and therapy monitoring. Bauer et al. provides an up-to-date overview of the methodology and relevance of 1H-MR spectroscopy (MRS) in the oncological primary and follow-up diagnosis of gliomas. The possibilities and limitations of this MR spectroscopic examination are evaluated on the basis of the available literature.
Jan Schaible, Lars Grenacher, Christian Stroszczynski et al.
The time interval from symptom onset to the diagnosis of chronic pancreatitis (CP) remains disproportionately long due to nonspecific symptoms and the absence of a definitive laboratory marker. According to the current S3 guideline, the morphological staging of CP should be based on the Cambridge Classification for CT/MRCP. Most radiologists morphologically associate CP with Cambridge Stage 4, which is characterized by classic calcifications. The subtle morphologies of earlier Cambridge Stages are often unrecognized, leading to delayed diagnosis. The aim of this study was to diagnose CP at Cambridge Stage 2 as the cause of unexplained upper abdominal discomfort.
